ARJUNA Therapeutics to present at the 2023 meeting of the American Association for Cancer Research

A CORUÑA, Spain - March 20, 2023 - PRLog -- ARJUNA Therapeutics announces that it will be presenting data at the 2023 American Association for Cancer Research meeting in Orlando, Florida, outlining single agent and combinatorial efficacy for its lead asset, Ag5, in Non Small Cell Lung Cancer. Dr Ross Breckenridge PhD FRCP said "We are pleased to be able to share encouraging data for Ag5 in this important indication, outline the completely novel mechanism of action and explored combinatorial treatment options that we believe will underpin the immediate next generation of cancer treatment".

ARJUNA Therapeutics is a preclinical stage oncology focussed biotech company developing an entirely new class of therapeutic small molecules based on small molecules synthesised by quantum chemistry. Ag5 is the first drug of the ARJUNA pipeline, with a unique cancer-specific mitochondrial mechanism of action, benign toxicity and excellent drug like properties including free passage across the blood brain barrier.

More information about the company can be found at www.arjunatherapeutics.com